Antileishmanial Activity of Tamoxifen by Targeting Sphingolipid Metabolism: A Review

References

• Pace D. Leishmaniasis. J Infect. 2014;69(Suppl 1):S10–8. doi:10.1016/j.jinf.2014.07.016
   PubMed Web of Science ®Google Scholar
• Regina S, Soares DC, Hirata CF. Cell death mechanisms in Leishmania amazonensis triggered by methylene blue-mediated antiparasitic photodynamic therapy. Photodiagnosis Photodyn Ther. 2018. doi:10.1016/j.pdpdt.2018.05.005
   Web of Science ®Google Scholar
• Tabbabi A. Review of Leishmaniasis in the Middle East and North Africa. Afr Health Sci. 2019;19:1329–1337. doi:10.4314/ahs.v19i1.4
   PubMed Web of Science ®Google Scholar
• Celes FS, Trovatti E, Khouri R, et al. DETC-based bacterial cellulose bio-curatives for topical treatment of cutaneous leishmaniasis. Sci Rep. 2016;6:1–11. doi:10.1038/srep38330
   PubMed Web of Science ®Google Scholar
• Jawed J, Majumdar S. Recent Trends in Leishmania Research: a Therapeutic Perspective. J Infect. 2018;1:1–4. doi:10.29245/2689-9981/2018/3.1120
   Google Scholar
• Ruiz-Postigo JA, Jain S, Mikhailov A, et al. Global leishmaniasis surveillance: 2019–2020, a baseline for the 2030 roadmap. Wkly Epidemiol Rec. 2021;35:401–420.
   Google Scholar
• Moein D, Masoud D, Saeed M, Abbas D. Epidemiological Aspects of Cutaneous Leishmaniasis during 2009–2016 in Kashan City, Central Iran. Korean J Parasitol. 2018;56:21–24.
   PubMed Web of Science ®Google Scholar
• Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet. 2018;392(10151):951–970. doi:10.1016/S0140-6736(18)31204-2
   PubMed Web of Science ®Google Scholar
• Trinconi CT, Miguel DC, Silber AM, et al. Tamoxifen inhibits the biosynthesis of inositolphosphorylceramide in Leishmania. Int J Parasitol Drugs Drug Resist. 2018;8:475–487.
   PubMed Web of Science ®Google Scholar
• Butts A, Martin JA, DiDone L, et al. Structure-Activity Relationships for the Antifungal Activity of Selective Estrogen Receptor Antagonists Related to Tamoxifen. PLoS One. 2015;10(5):1–16. doi:10.1371/journal.pone.0125927
   Web of Science ®Google Scholar
• Li F, Dou J, Wei L, Li S, Liu J. The selective estrogen receptor modulators in breast cancer prevention. Cancer Chemother Pharmacol. 2016;77:895–903. doi:10.1007/s00280-016-2959-0
   PubMed Web of Science ®Google Scholar
• Finney CA, Shvetcov A, Westbrook RF, Morris MJ, Jones NM. The selective estrogen receptor modulator tamoxifen protects against subtle cognitive decline and early markers of injury 24 h after hippocampal silent infarct in male Sprague-Dawley rats. Horm Behav. 2021;134:105016.
   PubMed Web of Science ®Google Scholar
• Pickar JH, Komm BS. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: a review of effects on the breast. Post Reprod Heal. 2015;21:112–121. doi:10.1177/2053369115599090
   PubMedGoogle Scholar
• Weinstock A, Gallego-Delgado J, Gomes C, et al. Tamoxifen activity against Plasmodium in vitro and in mice. Malar J. 2019;18:1–7. doi:10.1186/s12936-019-3012-7
   PubMed Web of Science ®Google Scholar
• Fanidi A, Pageaux JF, Courion C, Fayard JM, Laugier C. Growth inhibition and the regulation of cyclic AMP by the triphenylethylene anti-estrogen tamoxifen in the quail oviduct. Biol Cell. 1991;72:181–186. doi:10.1016/0248-4900(91)90092-2
   PubMed Web of Science ®Google Scholar
• Borgna JL. The elucidation of the antiestrogen and antitumoral mechanisms of tamoxifen. Bull Cancer. 1994;81:29–37.
   PubMedGoogle Scholar
• Shahbaz K. Tamoxifen: pharmacokinetics and Pharmacodynamics. Open Access J Pharm Res. 2017;1:1–8.
   Google Scholar
• Del Re M, Citi V, Crucitta S, et al. Pharmacogenetics of CYP2D6 and tamoxifen therapy: light at the end of the tunnel? Pharmacol Res. 2016;107:398–406. doi:10.1016/j.phrs.2016.03.025
   PubMed Web of Science ®Google Scholar
• Garg A, Singh B, Sharma R, Singh A, Kumar A. Selective Estrogen Receptor Modulators (SERMs): mechanistic Insights Against Microbial Infections. Curr Mol Med. 2019;20:102–115. doi:10.2174/1566524019666191014112133
   Web of Science ®Google Scholar
• Monzote L. Current treatment of leishmaniasis: a review. Open Antimicrob Agents J. 2009;1:9–19.
   Google Scholar
• DiPiro JT. Pharmacology & Therapeutics. Vol. 95. McGraw Hill Medical; 2008.
   Google Scholar
• Mosimann V, Neumayr A, Paris DH, Blum J. Liposomal amphotericin B treatment of Old World cutaneous and mucosal leishmaniasis: a literature review. Acta Trop. 2018;182:246–250. doi:10.1016/j.actatropica.2018.03.016
   PubMed Web of Science ®Google Scholar
• van Griensven J, Diro E. Visceral Leishmaniasis: recent Advances in Diagnostics and Treatment Regimens. Infect Dis Clin North Am. 2019;33:79–99. doi:10.1016/j.idc.2018.10.005
   PubMed Web of Science ®Google Scholar
• Rodrigo C, Weeratunga P, Fernando SD, Rajapakse S. Amphotericin B for treatment of visceral leishmaniasis: systematic review and meta-analysis of prospective comparative clinical studies including dose-ranging studies. Clin Microbiol Infect. 2018;24:591–598. doi:10.1016/j.cmi.2017.11.008
   PubMed Web of Science ®Google Scholar
• Miguel DC, Zauli-Nascimento RC, Yokoyama-Yasunaka JKU, et al. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections. J. Antimicrob. Chemother. 2009;63:365–368. doi:10.1093/jac/dkn509
   PubMed Web of Science ®Google Scholar
• Miguel DC, Yokoyama-Yasunaka JKU, Uliana SRB. Tamoxifen is effective in the treatment of Leishmania amazonensis infections in mice. PLoS Negl Trop Dis. 2008;2. doi:10.1371/journal.pntd.0000249
   PubMed Web of Science ®Google Scholar
• Eissa MM, Amer EI, El Sawy SMF. Leishmania major: activity of tamoxifen against experimental cutaneous leishmaniasis. Exp Parasitol. 2011;128:382–390.
   PubMed Web of Science ®Google Scholar
• Machado PRL. Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial. Trop Med Int Heal. 2018;23:936–942. doi:10.1111/tmi.13119
   PubMed Web of Science ®Google Scholar
• Trinconi CT, Reimão JQ, Coelho AC, Uliana SRB. Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis. J Antimicrob Chemother. 2016;71:1314–1322. doi:10.1093/jac/dkv495
   PubMed Web of Science ®Google Scholar
• Doroodgar M, Delavari M, Doroodgar M, et al. Tamoxifen Induces Apoptosis of Leishmania major Promastigotes in Vitro. Korean J Parasitol. 2016;54:9–14. doi:10.3347/kjp.2016.54.1.9
   PubMed Web of Science ®Google Scholar
• Morad SAF, Cabot MC. Tamoxifen regulation of sphingolipid metabolism–Therapeutic implications. Biochim Biophys Acta. 1851;1134–1145:2015.
   Google Scholar
• Morad SAF, Tan SF, Feith DJ, et al. Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia–Impact on enzyme activity and response to cytotoxics. Biochim Biophys Acta. 1851;919–928:2015.
   Google Scholar
• Landoni M, Piñero T, Soprano LL, et al. Tamoxifen acts on Trypanosoma cruzi sphingolipid pathway triggering an apoptotic death process. Biochem Biophys Res Commun. 2019;516:934–940. doi:10.1016/j.bbrc.2019.06.149
   PubMed Web of Science ®Google Scholar
• Reimão JQ, Uliana SRB. Tamoxifen alters cell membrane properties in Leishmania amazonensis promastigotes. Parasitol Open. 2018;4:4–9. doi:10.1017/pao.2018.3
   Google Scholar
• Miguel DC, Yokoyama-Yasunaka JKU, Andreoli WK, Mortara RA, Uliana SRB. Tamoxifen is effective against Leishmania and induces a rapid alkalinization of parasitophorous vacuoles harbouring Leishmania (Leishmania) amazonensis amastigotes. J Antimicrob Chemother. 2007;60:526–534. doi:10.1093/jac/dkm219
   PubMed Web of Science ®Google Scholar
• Trinconi CT, Reimão JQ, Yokoyama-Yasunaka JKU, Miguel DC, Uliana SRB. Combination therapy with tamoxifen and amphotericin B in experimental cutaneous leishmaniasis. Antimicrob Agents Chemother. 2014;58:2608–2613. doi:10.1128/AAC.01315-13
   PubMed Web of Science ®Google Scholar
• Coelho AC, Trinconi CT, Senra L, Yokoyama-Yasunaka JKU, Uliana SRB. Leishmania is not prone to develop resistance to tamoxifen. Int J Parasitol Drugs Drug Resist. 2015;5:77–83. doi:10.1016/j.ijpddr.2015.05.006
   PubMed Web of Science ®Google Scholar
• Machado PRL, Ribeiro CS, França-Costa J, et al. Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial. Trop Med Int Heal. 2018;23:936–942.
   PubMed Web of Science ®Google Scholar
• Abbasi A, Tan SF, Feith DJ, et al. The effect of tamoxifen on the growth of Leishmania major promastigotes and amastigotes in vitro. KAUMS J. 2015;19:54–59.
   Google Scholar
• Machado PRL, Ribeiro CS, França-Costa J, et al. Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial. Trop Med Int Health. 2018;23:936–942.
   PubMed Web of Science ®Google Scholar
• Trinconi CT, Reimao JQ, Bonano VI, et al. Topical tamoxifen in the therapy of cutaneous leishmaniasis. Parasitology. 2018;145:490–496.
   PubMed Web of Science ®Google Scholar